{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127058","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.199010+00:00","generated_at":"2026-05-30T00:42:30.667046+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Cell Therapeutics Q3 2024 net loss $3.0M, revenue $3.8M; OpRegen gets RMAT designation","bullets":["Net loss $3.0M ($0.02/sh) vs $7.1M ($0.04/sh) in Q3 2023; revenue $3.8M vs $1.2M.","Cash $32.7M expected to fund operations into Q1 2026.","OpRegen (RG6501) received RMAT designation from FDA for geographic atrophy secondary to AMD.","OPC1 spinal cord injury study start-up activities ongoing; ReSonance preclinical results presented.","Operating expenses $7.6M ($3.2M R&D, $4.4M G&A), down from $7.9M in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127058","json":"https://secwatch.observer/filing/0000950170-24-127058.json","markdown":"https://secwatch.observer/filing/0000950170-24-127058.md","text":"https://secwatch.observer/filing/0000950170-24-127058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/0000950170-24-127058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/lctx-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:42:30.667046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}